PASSAGE BIO, INC. Deferred Offering Costs
PASSAGE BIO, INC. (PASG) had Deferred Offering Costs of $200.00 thousand as of 2020-12-31, per its 10-K filed 2021-03-03.
Discontinued › Balance Sheet › Assets, Current
us-gaap:DeferredOfferingCosts · last filed 2021-03-03
- 2020-12-31: Deferred Offering Costs $200.00K.
- 2019-12-31: Deferred Offering Costs $1.70M.
| Period end | Deferred Offering Costs |
|---|---|
| 2020-12-31 | $200.00K 10-K · filed 2021-03-03 |
| 2019-12-31 | $1.70M 10-K · filed 2021-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |